Ilika plc (AIM:IKA), the advanced cleantech materials discovery company, is delighted to announce a new development project being undertaken by its biomedical subsidiary, Altrika Limited (“Altrika”) for the Industrial Technology Research Institute (“ITRI”) in Taiwan. The programme will make use of Altrika’s high throughput materials discovery capability for bio-functional polymers to support a key tissue regeneration research project run by ITRI’s Biomedical Engineering Research Lab (BEL).
Altrika improves human health through the discovery of novel materials which can enable the next generation of medical devices. It supplies and develops new products using materials which actively contribute to the prevention of disease and recovery from illness. Altrika has already commercialised two products, CryoSkin and MySkin, which are used for the treatment of burns.
ITRI is well known for its world-leading technical innovation. It pioneered commercial success in the semi-conductor industry in Taiwan, having developed the technology behind both UMC and TSMC, the world’s largest semiconductor fabrication company.
“This programme with ITRI is another vote of confidence from a world-leading organisation in Altrika and our materials discovery capabilities,” said Graeme Purdy, CEO of Ilika. “ITRI’s track record in commercializing novel technologies makes them an ideal partner for us and we are very excited by the potential of this novel form of treatment.”
“Altrika provides the answer to one of our key technical challenges in this development,” said Dr. Chungcheng Liu, General Director of ITRI BEL. “Their ability to screen such large libraries of materials so quickly will provide us with a highly functional and cost effective treatment. We are very pleased to be have secured them as our partner.”